Journal of
Clinical Medicine and Research

  • Abbreviation: J. Clin. Med. Res.
  • Language: English
  • ISSN: 2141-2235
  • DOI: 10.5897/JCMR
  • Start Year: 2009
  • Published Articles: 106

Full Length Research Paper

Treatment of recurrent refractory mantle cell lymphoma by thalidomide in combination with interferon

Lijie Han
  • Lijie Han
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar
Huifang Zhao
  • Huifang Zhao
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar
Qingsong Yin
  • Qingsong Yin
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar
Lin Chen
  • Lin Chen
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar
Yongping Song
  • Yongping Song
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar
Xudong Wei*
  • Xudong Wei*
  • Department of Hematology Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.
  • Search for this author on:
  • Google Scholar


  •  Received: 08 July 2014
  •  Accepted: 17 April 2015
  •  Published: 30 April 2015

References

Armitage JO, Coiffier B (2000). Activity of interferon-α in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann. Oncol. 11(3)359-361.
Crossref
 
D'Amato RJ, Loughran MS, Flynn E, Folkman J (1994). Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:4082-4085.
Crossref
 
Damaj G, Lefrere F, Delarue R, Varet B, Furman R, Hermine O (2003). Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 17(9):1914-1915.
Crossref
 
Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98(1):210-216.
Crossref
 
Davis TA, Maloney DG, Grillo AJ (2000). Combination immunotherapy of relapsed or refractory lowgrade or follicular non-Hodgkin's lymphoma with rituximab and interferonα-2a. Clin. Cancer Res. 6:2644-2652.
Pubmed
 
Haslett PAJ, Corral LG, Albert M, Kaplan G (1998). Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J. Exp. Med. 187(11)1885-1892.
Crossref
 
Kaufmann H, Raderer M, Wöhrer S, Püspök A, Bankier A, Zielinski C, Chott A, Drach J (2004). Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle eell lymphoma. Blood 104(8):2269-2271.
Crossref
 
Richardson P, Hidershima T, Anderson K (2002). Thalidomide: Emerging role in cancer medicine. Ann. Rev. Med. 53:629-657.
Crossref
 
Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G (2001). Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 86(9):951-958.
Pubmed
 
Wilson EA, Jobanputra S, Jackson R, Parker AN, McQuaker IG (2002). Response to thalidomide in chemotherapy-resistant mantle cell lymphoma:a case report.Br. J. HaematoI. 119(1)128-130.
Crossref

 

Copyright © 2024 Author(s) retain the copyright of this article.

This article is published under the terms of the Creative Commons Attribution License 4.0

Back to Vol. 7 No. 2
Back to articles
SUBSCRIBE TO RSS
SUBMIT MANUSCRIPT
CONFERENCES